SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-128896
Filing Date
2023-05-01
Accepted
2023-05-01 08:42:02
Documents
12
Period of Report
2023-05-01
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K d505148d8k.htm   iXBRL 8-K 23147
  Complete submission text file 0001193125-23-128896.txt   147711

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA acrv-20230501.xsd EX-101.SCH 2838
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE acrv-20230501_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acrv-20230501_pre.xml EX-101.PRE 11699
6 EXTRACTED XBRL INSTANCE DOCUMENT d505148d8k_htm.xml XML 3459
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41551 | Film No.: 23870365
SIC: 2834 Pharmaceutical Preparations